236 related articles for article (PubMed ID: 11415906)
1. Dynamic contrast-enhanced T2*-weighted MR imaging of tumefactive demyelinating lesions.
Cha S; Pierce S; Knopp EA; Johnson G; Yang C; Ton A; Litt AW; Zagzag D
AJNR Am J Neuroradiol; 2001; 22(6):1109-16. PubMed ID: 11415906
[TBL] [Abstract][Full Text] [Related]
2. Distinguishing tumefactive demyelinating lesions from glioma or central nervous system lymphoma: added value of unenhanced CT compared with conventional contrast-enhanced MR imaging.
Kim DS; Na DG; Kim KH; Kim JH; Kim E; Yun BL; Chang KH
Radiology; 2009 May; 251(2):467-75. PubMed ID: 19261924
[TBL] [Abstract][Full Text] [Related]
3. Proton MR spectroscopy of tumefactive demyelinating lesions.
Saindane AM; Cha S; Law M; Xue X; Knopp EA; Zagzag D
AJNR Am J Neuroradiol; 2002 Sep; 23(8):1378-86. PubMed ID: 12223381
[TBL] [Abstract][Full Text] [Related]
4. Performance of Apparent Diffusion Coefficient Values and Conventional MRI Features in Differentiating Tumefactive Demyelinating Lesions From Primary Brain Neoplasms.
Mabray MC; Cohen BA; Villanueva-Meyer JE; Valles FE; Barajas RF; Rubenstein JL; Cha S
AJR Am J Roentgenol; 2015 Nov; 205(5):1075-85. PubMed ID: 26496556
[TBL] [Abstract][Full Text] [Related]
5. Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements.
Hu LS; Baxter LC; Smith KA; Feuerstein BG; Karis JP; Eschbacher JM; Coons SW; Nakaji P; Yeh RF; Debbins J; Heiserman JE
AJNR Am J Neuroradiol; 2009 Mar; 30(3):552-8. PubMed ID: 19056837
[TBL] [Abstract][Full Text] [Related]
6. Characterization of tumefactive demyelinating lesions using MR imaging and in-vivo proton MR spectroscopy.
Malhotra HS; Jain KK; Agarwal A; Singh MK; Yadav SK; Husain M; Krishnani N; Gupta RK
Mult Scler; 2009 Feb; 15(2):193-203. PubMed ID: 19181773
[TBL] [Abstract][Full Text] [Related]
7. MRI Findings in Tumefactive Demyelinating Lesions: A Systematic Review and Meta-Analysis.
Suh CH; Kim HS; Jung SC; Choi CG; Kim SJ
AJNR Am J Neuroradiol; 2018 Sep; 39(9):1643-1649. PubMed ID: 30115676
[TBL] [Abstract][Full Text] [Related]
8. Histogram analysis of apparent diffusion coefficient maps for differentiating primary CNS lymphomas from tumefactive demyelinating lesions.
Lu SS; Kim SJ; Kim N; Kim HS; Choi CG; Lim YM
AJR Am J Roentgenol; 2015 Apr; 204(4):827-34. PubMed ID: 25794073
[TBL] [Abstract][Full Text] [Related]
9. Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected].
Lev MH; Ozsunar Y; Henson JW; Rasheed AA; Barest GD; Harsh GR; Fitzek MM; Chiocca EA; Rabinov JD; Csavoy AN; Rosen BR; Hochberg FH; Schaefer PW; Gonzalez RG
AJNR Am J Neuroradiol; 2004 Feb; 25(2):214-21. PubMed ID: 14970020
[TBL] [Abstract][Full Text] [Related]
10. The role of dynamic susceptibility contrast-enhanced perfusion MR imaging in differentiating between infectious and neoplastic focal brain lesions: results from a cohort of 100 consecutive patients.
Floriano VH; Torres US; Spotti AR; Ferraz-Filho JR; Tognola WA
PLoS One; 2013; 8(12):e81509. PubMed ID: 24324699
[TBL] [Abstract][Full Text] [Related]
11. Dynamic contrast-enhanced T2*-weighted MR imaging of gliomatosis cerebri.
Yang S; Wetzel S; Law M; Zagzag D; Cha S
AJNR Am J Neuroradiol; 2002 Mar; 23(3):350-5. PubMed ID: 11900998
[TBL] [Abstract][Full Text] [Related]
12. Utility of proton MR spectroscopy for differentiating typical and atypical primary central nervous system lymphomas from tumefactive demyelinating lesions.
Lu SS; Kim SJ; Kim HS; Choi CG; Lim YM; Kim EJ; Kim DY; Cho SH
AJNR Am J Neuroradiol; 2014 Feb; 35(2):270-7. PubMed ID: 23928144
[TBL] [Abstract][Full Text] [Related]
13. Perfusion and diffusion MR imaging in enhancing malignant cerebral tumors.
Calli C; Kitis O; Yunten N; Yurtseven T; Islekel S; Akalin T
Eur J Radiol; 2006 Jun; 58(3):394-403. PubMed ID: 16527438
[TBL] [Abstract][Full Text] [Related]
14. Correlation of relative permeability and relative cerebral blood volume in high-grade cerebral neoplasms.
Provenzale JM; York G; Moya MG; Parks L; Choma M; Kealey S; Cole P; Serajuddin H
AJR Am J Roentgenol; 2006 Oct; 187(4):1036-42. PubMed ID: 16985154
[TBL] [Abstract][Full Text] [Related]
15. Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging.
Knopp EA; Cha S; Johnson G; Mazumdar A; Golfinos JG; Zagzag D; Miller DC; Kelly PJ; Kricheff II
Radiology; 1999 Jun; 211(3):791-8. PubMed ID: 10352608
[TBL] [Abstract][Full Text] [Related]
16. Can permeability measurements add to blood volume measurements in differentiating tumefactive demyelinating lesions from high grade gliomas using perfusion CT?
Jain R; Ellika S; Lehman NL; Scarpace L; Schultz LR; Rock JP; Rosenblum M; Mikkelsen T
J Neurooncol; 2010 May; 97(3):383-8. PubMed ID: 19830525
[TBL] [Abstract][Full Text] [Related]
17. Dynamic contrast-enhanced susceptibility-weighted perfusion imaging of intracranial tumors: a study using a 3T MR scanner.
Sentürk S; Oğuz KK; Cila A
Diagn Interv Radiol; 2009 Mar; 15(1):3-12. PubMed ID: 19263367
[TBL] [Abstract][Full Text] [Related]
18. Dynamic susceptibility contrast-enhanced perfusion and conventional MR imaging findings for adult patients with cerebral primitive neuroectodermal tumors.
Law M; Kazmi K; Wetzel S; Wang E; Iacob C; Zagzag D; Golfinos JG; Johnson G
AJNR Am J Neuroradiol; 2004; 25(6):997-1005. PubMed ID: 15205137
[TBL] [Abstract][Full Text] [Related]
19. Tumefactive demyelinating lesions: conventional and advanced magnetic resonance imaging.
Enzinger C; Strasser-Fuchs S; Ropele S; Kapeller P; Kleinert R; Fazekas F
Mult Scler; 2005 Apr; 11(2):135-9. PubMed ID: 15794384
[TBL] [Abstract][Full Text] [Related]
20. Mass lesions in the brain: tumor or multiple sclerosis? Clinical and imaging characteristics and course from a single reference center.
Kilic AK; Kurne AT; Oguz KK; Soylemezoglu F; Karabudak R
Turk Neurosurg; 2013; 23(6):728-35. PubMed ID: 24310455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
